^
Association details:
| Biomarker: | ER positive |
|---|---|
| Cancer: | Estrogen Receptor Positive Breast Cancer |
| Drug: | Orserdu (elacestrant) (Selective estrogen receptor degrader) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Elacestrant Improves Progression-Free Survival After Endocrine Therapy for Estrogen Receptor-Positive Metastatic Breast Cancer
Published date:
03/28/2022
Excerpt:
In the phase III EMERALD trial, treatment with elacestrant significantly improved progression-free survival compared with investigator’s choice in patients with estrogen receptor-positive metastatic breast cancer that progressed on prior endocrine therapies.
DOI:
10.1093/oncolo/oyac015
Trial ID:
Source:
Title:
Study of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/HER2- Breast Cancer
Excerpt:
......
Trial ID:
Source:
Title:
Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)
Excerpt:
...- Female or male patients with histologically confirmed ER positive (regardless of PR), HER2 negative breast cancer, according to local pathologist:...
Trial ID:
More C2 evidence
Source:
Title:
This study has 2 phases: a Phase 1b evaluation of elacestrant in combination with abemaciclib followed by a randomized Phase 2 evaluation of elacestrant alone or in combination with abemaciclib in women and men with brain metastases from ER positive, HER-2 negative breast cancer. Este estudio tiene 2 fases: una evaluación de Fase 1b de elacestrant en combinación con abemaciclib seguida de una evaluación randomizada de Fase 2 de elacestrant solo o en combinación con abemaciclib en mujeres y hombres con metástasis cerebrales causadas por un cáncer de mama con receptores de estrógeno y HER-2 negativo.
Excerpt:
...Patient must have ER positive, HER-2 negative tumor status as confirmed by local laboratory testing either from a fresh biopsy or from an archival tissue obtained no more than 2 years prior to signing of the informed consent form. ...
Trial ID:
